Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Integrating Evidence for Improved Outcomes in PH

Integrating Evidence for Improved Outcomes in PH

Updates on Pulmonary Hypertension Clinical Trials

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    Despite new mechanisms of action and updated clinical trial data for treatment strategies in pulmonary hypertension, HCPs continue to face challenges when treating pediatric patients, applying recent clinical trial data, and managing vasoreactivity in pulmonary hypertension. Tune in for some helpful tips from the experts in this journal club setting.

     

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Richard Channick, MD
    Director, Pulmonary Vascular Disease Program
    UCLA Medical Center
    Los Angeles, CA

    Dr. Channick has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Aria CV, Janssen

    Vallerie McLaughlin, MD
    Professor, Internal Medicine
    University of Michigan
    Ann Arbor, MI

    Dr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months.
    Research: Aerovate, Altavant, Gossamer Bio, Janssen, Merck, SoniVie
    Consulting fees: Aerami, Aerovate, Altavant, Bayer, Caremark, CorVista, Gossamer Bio, Janssen, Merck, United Therapeutics

    Ioana Preston, MD
    Associate Professor of Medicine
    Tufts University School of Medicine
    Boston, MA

    Dr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Acceleron/Merck, Actelion/Janssen, Keros, Liquidia, Respira, United Therapeutics
    Consulting fees: Acceleron/Merck, Actelion/Janssen, Aerovate, Gossamer, Keros, Liquidia, Respira, United Therapeutics

    Kelly Chin, MD 
    Pulmonologist
    UT Southwestern Medical Center
    Dallas, TX

    Dr. Chin has reported the following relevant financial relationships or relationships with ineligible companies for any amount during the past 24 months:
    Research support: Gossamer Bio, Janssen, Merck, Untied Therapeutics
    Consulting fees: Gossamer Bio, Janssen, Merck, Untied Therapeutics

    Richard A. Krasuski, MD 
    Cardiologist
    Duke University Hospital
    Durham, NC

    Dr. Krasuski has reported the following relevant financial relationships or relationships with ineligible companies for any amount during the past 24 months:
    Research: Actelion/Janssen, Adult Congenital Heart Association, Edwards Lifesciences, Gradient Denervation Technologies, and Medtronic
    Consulting fees: Actelion/Janssen, Bayer, Gore, Medtronic, and Neptune Medical

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Prerna Poojary, PhD has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
  • Learning Objectives

  • Target Audience

    This activity is designed to meet the educational needs of cardiologists and pulmonologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with pulmonary hypertension.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 9/30/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.015 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-084-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care. 

  • Commercial Support

    This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and Merck Sharp & Dohme LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule14 Oct 2024